A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 77
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : KRAS
Long Form : Kirsten rat sarcoma
No. Year Title Co-occurring Abbreviation
2020 A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. ATO, d-VC, VC
2020 A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma. CNA, DCB, ICI, LUAD, PFS, TMB
2020 Allele-Specific PCR for KRAS Mutation Detection Using Phosphoryl Guanidine Modified Primers. AS-PCR, PG
2020 Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study. ALK, EGFR, NSCLC, VTE
2020 Association of promoter methylation of RASSF1A and KRAS mutations in non-small cell lung carcinoma in Kashmiri population (India). ADC, ASO-PCR, NSCLC, RASSF1A, SCC, TSG
2020 Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan. AUC, EGFR, NSCLC, TP53
2020 Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. ALK, EGFR, ERRB2, NSCLC, RET, ROS1, TKI, WTD
2020 Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. HRAS, MIR143, miRNA, NRAS, RAS
2020 In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. ADCC, CRC, ECCs, EGFR, NK, TNBC
10  2020 KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. NSCLC
11  2020 KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. HRs, NSCLC, ORR, OS, PFS, RCTs, SLR
12  2020 Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. CRC, MCs, miRNAs
13  2020 Quantitative structure-activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors. ADMET, CoMFA, CoMSIA, fs, MD, NSCLC, QMEAN, QSAR
14  2020 Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study. ADC, AUC, CRLM, ROC
15  2020 The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis. PanIN, PDAC
16  2020 The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. BRAF, RAS
17  2020 Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. ALP, CI, CRC, mCRC
18  2019 Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. CRC, CTC, ctDNA, LM, PCR
19  2019 Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene. nsSNPs
20  2019 Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation. AUC, CI, EGFR, NSCLC, ROC
21  2019 Human Papillomavirus Infection, p16INK4a Expression and Genetic Alterations in Vietnamese Cervical Neuroendocrine Cancer. EGFR, HPV, NRAS, PCR
22  2019 Impact of Genetics on Neoadjuvant Therapy with Complete Pathological Response in Metastatic Colorectal Cancer: Case Report and Review of the Literature. ---
23  2019 KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma. ---
24  2019 Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway. CCK-8, CRC, p-AKT, p-PI3K, PI3K, qRT-PCR, SNHG14
25  2019 Relationship between KRAS mutations and dual time point 18F-FDG PET/CT imaging in colorectal liver metastases. CRLM, DeltaSUVmax, RI
26  2019 Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder. DCAI, HSQC, SHG, TROSY
27  2019 Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite non-malignant cytology. APS, ICECOLD PCR, MPE, NSCLC
28  2019 Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. CDH1, PUC, TERT, UC
29  2019 Targeting the KRAS, p38alpha, and NF-kappaB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor. FACS, MAPK, mRNA, NF-kappaB, siRNA
30  2019 Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. cfDNA, EGFR, MET, NSCLC, PI3KCA, TKIs
31  2019 ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. IL17RD, MAPK, ZEB1
32  2018 Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis. IGF1R, IR, NSCLC
33  2018 Allosteric Inhibitor of KRas Identified Using a Barcoded Assay Microchip Platform. PCCs
34  2018 Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. AVC, BRAF, ErbB, NRAS, PI3K, RAS, TGF-beta, Wnt
35  2018 Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma. NSCLC
36  2018 Contribution of smoking habit to the prognosis of stage I KRAS-mutated non-small cell lung cancer. MHS, NLS, NSCLC, OS
37  2018 Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance. miRNA-143, RT-PCR
38  2018 Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. CT, mCRC, OS, PFS, SRT
39  2018 MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma. miR-622
40  2018 Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. ALK, BRAF, CI, EGFR, HR, NSCLC
41  2018 The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy. EGFR, NSCLC
42  2018 Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. ERK, HCC, MAPK, PI3K
43  2018 Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition. KRASi
44  2017 Clinicopathological and Corresponding Genetic Features of Colorectal Signet Ring Cell Carcinoma. ---
45  2017 Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. ALK, cfDNA, NSCLC
46  2017 Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer. CI, EGFR, NSCLC, OS
47  2017 Genetic alterations in Japanese extrahepatic biliary tract cancer. AVC, BTC, EBDC, GBC, PIK3CA, SMAD4, TP53
48  2017 MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. 5-FU, BRAF, CRC, ERK, MEK
49  2017 Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. CEA, LDH, OS
50  2016 Emerging targeted therapies in non-small cell lung cancer. ALK, BRAF, EGFR, MET, RET
51  2016 Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches. ---
52  2016 Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. ATG7
53  2016 MiR-622 inhibited colorectal cancer occurrence and metastasis by suppressing K-Ras. CRC, miRNAs
54  2016 Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. BSC, HR, NSCLC, OS, PFS
55  2016 Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma. miRNAs, MMP2, mRNA, NHA, PCNA
56  2015 Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. ALK, CI, COPD, EGFR, NSCLC
57  2015 Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations. AIS, CT, EGFR, IAC, mGGO, MIA, pGGO, sGGO
58  2015 Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide. ASODN, IGF-IR, mRNA, PCR-SSP
59  2015 Treatment of metastatic colorectal cancer: focus on panitumumab. EGFR, mCRC
60  2015 [Role of HER2 in NSCLC]. ALK, EGFR, HER2, NSCLC, TKIs
61  2014 A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. CHO, EGFR, i.v, IL, NSCLC
62  2014 Apoptosis induction by 13-acetoxyrolandrolide through the mitochondrial intrinsic pathway. NF-kappaB
63  2014 Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. GLUT1
64  2014 Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. CBs, EGFR, FNA
65  2014 Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. ---
66  2013 The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. EGFR, ICER, QALY, RCTs, VEGF, WT
67  2013 The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. ALK, EBUS-TBNA, EGFR, FISH
68  2012 Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. EGFR, SCC
69  2012 Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). CI, ERMETIC, HR, LR, OS, PFS, TKI
70  2012 KRAS mutations and subtyping in colorectal cancer in Jordanian patients. CRC
71  2012 Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. CNGs, EGFR
72  2011 Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification. EGFR
73  2010 KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography. ---
74  2010 Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. EGFR, Ig, OPUS, PSF
75  2010 The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. PNA
76  2009 EphA2 in the early pathogenesis and progression of non-small cell lung cancer. ERK, GTPase, NSCLC
77  2009 Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. CA19-9